Top Markets
#1 Helium Helium +109.80%
#2 MowCat MowCat +84.82%
#3 Seeker Seeker +49.80%
#4 UnifAI Network UnifAI Network +35.50%
#5 TENDIES TENDIES +30.52%
#6 Zylo Ecosystem Zylo Ecosystem +22.07%
#7 Tensor Tensor +21.07%
#8 Pons Pons +19.96%
#9 MarsCoin MarsCoin +17.58%
#10 pipedog pipedog +16.58%
Coin of the day
Helium Helium
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Peringkat dalam Saham #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Harga Saham
$9.50
Terakhir disinkronkan: 2025-01-08
Kapitalisasi Pasar
$819.52M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Poseida Therapeutics, Inc. (PSTX)

Kategori

Healthcare
Rasio P/S untuk Poseida Therapeutics, Inc. (PSTX)
Rasio P/S per August 2026 TTM: 14.31
Menurut laporan keuangan dan harga saham terbaru dari Poseida Therapeutics, Inc., rasio P/S saat ini (TTM) adalah 14.31. Pada akhir 2022, rasio P/S perusahaan adalah 2.92.
Riwayat rasio P/S untuk Poseida Therapeutics, Inc. dari 2016 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
2026 (TTM) 14.31 205.78%
2023 4.68 60.18%
2022 2.92 -99.98%
2021 13.55K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 204.33 119.21%
2016 93.21 0.00%
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -28.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -29.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -79.37%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -21.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH